Smead Capital Management’s AbbVie ABBV Stock Holding History

Smead Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-394,809	Closed	-$26.5M	–	28
2015 Q2	$26.5M	Buy	394,809 +41,404	+12%	+$2.7M	1.73%	26
2015 Q1	$20.7M	Buy	353,405 +56,464	+19%	+$3.41M	1.52%	27
2014 Q4	$19.4M	Sell	296,941 -52,862	-15%	-$3.33M	1.79%	24
2014 Q3	$20.2M	Buy	349,803 +9,217	+3%	+$512K	2.18%	22
2014 Q2	$19.2M	Buy	340,586 +15,816	+5%	+$830K	2.09%	22
2014 Q1	$16.7M	Buy	324,770 +40,140	+14%	+$2.03M	2.01%	23
2013 Q4	$15M	Buy	284,630 +22,673	+9%	+$1.11M	2.07%	23
2013 Q3	$11.7M	Buy	261,957 +40,879	+18%	+$1.81M	1.9%	24
2013 Q2	$9.14M	Buy	+221,078	New	+$9.67M	1.85%	26

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Smead Capital Management's ABBV Position: Q3 2015 in Review

Smead Capital Management sold out of AbbVie (ABBV) in Q3 2015, closing a stake of 394,809 shares — an estimated $26.5M sold.

Smead Capital Management first reported a position in ABBV in Q2 2013 and held it in 9 quarters. The position peaked at $26.5M in Q2 2015. 1,604 funds tracked by Wall St. Rank hold ABBV as of Q3 2015.

Smead Capital Management reported no remaining AbbVie position as of Q3 2015 after selling out during the quarter.
Smead Capital Management sold 394,809 AbbVie shares in Q3 2015, an estimated $26.5M.
Smead Capital Management first reported a position in AbbVie in Q2 2013 and held it in 9 quarters.
Smead Capital Management's AbbVie position peaked at $26.5M in Q2 2015.
1,604 funds tracked by Wall St. Rank held AbbVie as of Q3 2015.

Based on Smead Capital Management's 13F filing for Q3 2015, filed 9 Nov 2015.